Mechanism of glucocerebrosidase activation and dysfunction in Gaucher disease unraveled by molecular dynamics and deep learning
暂无分享,去创建一个
Arvind Ramanathan | Charit Taneja | Mehr Mathew | Maria I. New | Tony Yuen | Shozeb Haider | Debsindhu Bhowmik | Raquel Romero | Mone Zaidi | Daria Lizneva | Se-Min Kim | A. Ramanathan | T. Yuen | D. Bhowmik | S. Haider | Li Sun | M. Zaidi | M. New | Daria Lizneva | Li Sun | Lubna Bashir Munshi | Seher Javaid | Madison Bloch | Alina Rahimova | Ayesha Khan | R. Romero | Alina E. Rahimova | Charit Taneja | Seher Javaid | Ayesha Khan | L. Munshi | Se-Min Kim | Madison Bloch | Mehr Mathew
[1] N. Radin,et al. Mechanism of activation of glucocerebrosidase by co-beta-glucosidase (glucosidase activator protein). , 1981, Biochimica et biophysica acta.
[2] Marc N. Offman,et al. Comparison of a molecular dynamics model with the X-ray structure of the N370S acid-beta-glucosidase mutant that causes Gaucher disease. , 2011, Protein engineering, design & selection : PEDS.
[3] Alexandre M. J. J. Bonvin,et al. CPORT: A Consensus Interface Predictor and Its Performance in Prediction-Driven Docking with HADDOCK , 2011, PloS one.
[4] A. Tylki-Szymańska,et al. Gaucher disease due to saposin C deficiency, previously described as non-neuronopathic form--no positive effects after 2-years of miglustat therapy. , 2011, Molecular genetics and metabolism.
[5] Gregory A Petsko,et al. Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. , 2006, Nature chemical biology.
[6] F. Felicetti,et al. The N370S (Asn370-->Ser) mutation affects the capacity of glucosylceramidase to interact with anionic phospholipid-containing membranes and saposin C. , 2005, The Biochemical journal.
[7] D. Jain,et al. Gaucher disease gene GBA functions in immune regulation , 2012, Proceedings of the National Academy of Sciences.
[8] M. Horowitz,et al. Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant. , 2011, Blood Cells, Molecules & Diseases.
[9] K. Sandhoff,et al. Lysosomal degradation of membrane lipids , 2010, FEBS letters.
[10] R. Schultz-Heienbrok,et al. Crystal structures of human saposins C andD: implications for lipid recognition and membrane interactions. , 2008, Structure.
[11] W. Qin,et al. Functional Organization of Saposin C , 1996, The Journal of Biological Chemistry.
[12] Jeffrey D. Evanseck,et al. Chapter 13 Principal Components Analysis: A Review of its Application on Molecular Dynamics Data , 2006 .
[13] D. Ritchie,et al. Evaluation of Protein Docking Predictions Using Hex 3.1 in CAPRI Rounds 1{2 , 2002 .
[14] D. Tieleman,et al. The MARTINI force field: coarse grained model for biomolecular simulations. , 2007, The journal of physical chemistry. B.
[15] R. L. Lieberman,et al. A Guided Tour of the Structural Biology of Gaucher Disease: Acid-β-Glucosidase and Saposin C , 2011, Enzyme research.
[16] David W Ritchie,et al. Recent progress and future directions in protein-protein docking. , 2008, Current protein & peptide science.
[17] Oliver Beckstein,et al. MDAnalysis: A toolkit for the analysis of molecular dynamics simulations , 2011, J. Comput. Chem..
[18] Marc N. Offman,et al. Molecular Basis of Reduced Glucosylceramidase Activity in the Most Common Gaucher Disease Mutant, N370S , 2010, The Journal of Biological Chemistry.
[19] R. Brady,et al. Prevalence of nine mutations among Jewish and non-Jewish Gaucher disease patients. , 1993, American journal of human genetics.
[20] P. Kaplan,et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. , 2000, Archives of internal medicine.
[21] Carl Doersch,et al. Tutorial on Variational Autoencoders , 2016, ArXiv.
[22] K. Xia,et al. Glucocerebrosidase Gene L444P mutation is a risk factor for Parkinson's disease in Chinese population , 2010, Movement disorders : official journal of the Movement Disorder Society.
[23] Li Han,et al. Evaluation of Dimensionality-reduction Methods from Peptide Folding-unfolding Simulations. , 2013, Journal of chemical theory and computation.
[24] G. Privé,et al. Crystal structures of saposins A and C , 2006, Protein science : a publication of the Protein Society.
[25] G. Rennert,et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients , 2009, American journal of hematology.
[26] D. Ritchie,et al. Protein docking using spherical polar Fourier correlations , 2000, Proteins.
[27] S. Weiler,et al. Identification of the binding and activating sites of the sphingolipid activator protein, saposin C, with glucocerebrosidase , 1995, Protein science : a publication of the Protein Society.
[28] Seon-Yong Jeong,et al. Clinical and genetic characteristics of Korean patients with Gaucher disease. , 2011, Blood cells, molecules & diseases.
[29] C. Schütte,et al. Supplementary Information for “ Constructing the Equilibrium Ensemble of Folding Pathways from Short Off-Equilibrium Simulations ” , 2009 .
[30] Holger Gohlke,et al. The Amber biomolecular simulation programs , 2005, J. Comput. Chem..
[31] D. Kern,et al. Dynamic personalities of proteins , 2007, Nature.
[32] Shang Gao,et al. Deep clustering of protein folding simulations , 2018 .
[33] A. Vasella,et al. Glycosidase mechanisms. , 2002, Current opinion in chemical biology.
[34] J. K. Park,et al. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. , 2000, American journal of human genetics.
[35] The studies on substrate, product and inhibitor binding to a wild-type and neuronopathic form of human acid-β-glucosidase , 2007, Journal of molecular modeling.
[36] Shang Gao,et al. Deep clustering of protein folding simulations , 2018, BMC Bioinformatics.
[37] G. Grabowski,et al. Human acid beta-glucosidase. Use of inhibitory and activating monoclonal antibodies to investigate the enzyme's catalytic mechanism and saposin A and C binding sites. , 1991, The Journal of biological chemistry.
[38] R. Tamargo,et al. The role of saposin C in Gaucher disease. , 2012, Molecular genetics and metabolism.
[39] W. V. Gunsteren,et al. Validation of the 53A6 GROMOS force field , 2005, European Biophysics Journal.
[40] P. Gómez-Puertas,et al. An evolutionary and structure‐based docking model for glucocerebrosidase–saposin C and glucocerebrosidase–substrate interactions—Relevance for Gaucher disease , 2008, Proteins.
[41] Gianni De Fabritiis,et al. Dimensionality reduction methods for molecular simulations , 2017, ArXiv.
[42] Thomas Kolter,et al. Principles of lysosomal membrane degradation: Cellular topology and biochemistry of lysosomal lipid degradation. , 2009, Biochimica et biophysica acta.
[43] J. Sussman,et al. X‐ray structure of human acid‐β‐glucosidase, the defective enzyme in Gaucher disease , 2003, EMBO reports.
[44] E. Sidransky. Gaucher disease: insights from a rare Mendelian disorder. , 2012, Discovery medicine.
[45] Hongyu Zhao,et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage , 2010, Proceedings of the National Academy of Sciences.
[46] Y. Eto,et al. Clinical and Molecular Characteristics of Japanese Gaucher Disease , 1999, Neurochemical Research.
[47] G. Grabowski. Phenotype, diagnosis, and treatment of Gaucher's disease , 2008, The Lancet.
[48] A. Bonvin,et al. The HADDOCK web server for data-driven biomolecular docking , 2010, Nature Protocols.
[49] E. Sidransky,et al. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA) , 2008, Human mutation.
[50] Ying Sun,et al. Saposin C Is Required for Normal Resistance of Acid β-Glucosidase to Proteolytic Degradation* , 2003, Journal of Biological Chemistry.
[51] E. Sidransky,et al. Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease , 2000, Human mutation.